Immunology.
Immunology
Autoimmune & Inflamation
With populations ageing and becoming more overweight and obese - two of the major risk factors for developing the condition - the rate of osteoarthritis is set to increase substantially in the coming decades. This expected rise makes the need for better treatments ever more urgent.
Expert members from the American College of Rheumatology (ACR) and the European League Against Rheumatism Guidelines (EULAR) have identified several unmet needs to address this increasing burden. These include:
The development of disease modifying osteoarthritis drugs, such as local delivery of anti-inflammatory cytokines; and
Investigating pooled/combination treatments, which reflect everyday clinical practice.
DNX is developing two new molecules (DNX-114 and DNX-314) with long-action that have the potential of addressing both of the above-identified unmet needs in this therapeutic area.
Reference Resources
*American College of Rheumatology. Retrieved Jun. 2015 from http://www.rheumatology.org/
*American Academy of Orthopaedic Surgeons. Retrieved Jun. 2015 from http://www.aaos.org/home.asp
*Arthritis Research UK. Retrieved Jun. 2015 from http://www.arthritisresearchuk.org/